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During 1999 to 2000, we identified HIV-infected per-
sons with new episodes of tuberculosis (TB) at 10 hospitals
in Lima, Peru, and a random sample of other Lima resi-
dents with TB. Multidrug-resistant (MDR)-TB was docu-
mented in 35 (43%) of 81 HIV-positive patients and 38
(3.9%) of 965 patients who were HIV-negative or of
unknown HIV status (p < 0.001). HIV-positive patients with
MDR-TB were concentrated at three hospitals that treat the
greatest numbers of HIV-infected persons with TB. Of
patients with TB, those with HIV infection differed from
those without known HIV infection in having more frequent
prior exposure to clinical services and more frequent pre-
vious TB therapy or prophylaxis. However, MDR-TB in HIV-
infected patients was not associated with previous TB ther-
apy or prophylaxis. MDR-TB is an ongoing problem in HIV-
infected persons receiving care in public hospitals in Lima
and Callao; they represent sentinel cases for a potentially
larger epidemic of nosocomial MDR-TB. 
M
ultidrug-resistant tuberculosis (MDR-TB) threatens
global TB control and has been identified in almost
all surveyed countries. During 1994 to 1997, the World
Health Organization (WHO)-International Union against
Tuberculosis and Lung Disease identified high prevalences
of MDR-TB in the former Soviet Union, Asia, the
Dominican Republic, and Argentina (1).
MDR-TB has been associated with inadequate treat-
ment regimens, poor adherence to treatment, poorly man-
aged TB-control programs, and unenforced hospital infec-
tion control programs, as well as HIV infection (2). HIV
infection influences the natural history of TB in several
ways: active TB occurs within 6 months of acquiring
Mycobacterium tuberculosis infection in 37% of persons
with HIV-induced immunosuppression (3) but occurs in
2% of immunocompetent adults during the first year after
acquiring M. tuberculosis infection (4). HIV-infected per-
sons with TB also have increased frequency of dissem-
inated and meningeal disease, other extrapulmonary dis-
eases, atypical clinical signs and symptoms, drug-related
adverse events, and negative sputum smears for acid-fast
bacilli (5).
Nosocomial outbreaks of MDR-TB involving HIV-
infected persons have occurred in the United States and
other industrialized countries (6–9), but improved treat-
ment and hospital infection control programs have con-
tained these initial outbreaks of MDR-TB. However, such
outbreaks are increasingly recognized in countries with
more limited resources (10,11). 
In Peru, the National TB Control Program received
reports of 35,685 new TB cases in 1999 (incidence
141.4/100,000) (12). Passive reporting to the National TB
Control Program showed HIV prevalences from 1% to
1.5% in TB patients during 1996 to 1999 (12), but prospec-
tive testing of 1,043 patients with a new event of TB in
Lima and Callao from September to October 1999 found
HIV seropositivity in 2.3% (P.E. Campos, unpub. data).
Furthermore, TB was the AIDS-defining illness in 10,939
(28%) AIDS cases in Peru (13), and 50% of persons with
AIDS in Peru develop TB at some point in their disease.
A National TB Control Program survey during 1999
found MDR-TB in 57 (3%) of 1,879 Peruvians with a first
episode of TB and in 32 (12.3%) of 260 with previously
treated TB (14). Of 2,101 TB patients in that survey, 8 had
a previous diagnosis of HIV infection. In 1997, at the Dos
de Mayo Hospital in Lima, which provides care to the
largest number of HIV-infected persons, 9 (34.6%) of 26
HIV-infected patients with TB had MDR-TB (15).
Mortality rates during TB treatment of Peruvian HIV-
infected patients has been high; 63%, 51%, 49%, and 39%
of patients with a first episode of TB died during treatment
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ly (12,16). These rates contrast with a mortality rate of 9%
in HIV-infected persons with pulmonary TB in Haiti (17).
Treatment regimens prescribed for TB in developing coun-
tries are rarely based on susceptibility testing, and since
1987, HIV-infected patients with a first episode of TB in
Peru have received a standard course of rifampin, isoni-
azid, pyrazinamide, and ethambutol in compliance with
WHO recommendations (18). Therefore, MDR-TB might
contribute to the high mortality rate for TB in HIV-infec-
ted Peruvians.
We performed this study to further characterize the
prevalence and pattern of MDR-TB in HIV-infected adults
in Lima and the adjacent port of Callao in Peru and to
explore preventable risk factors that could be used to
design, implement, and evaluate better preventive and
therapeutic interventions.
Methods
Study Design and Population
This study was designed to evaluate the prevalence of
MDR-TB in HIV-infected patients >18 years of age and to
assess potential risk factors for MDR-TB in HIV-infected
persons with TB. The study was carried out from February
1999 to January 2000 in Lima and Callao. Lima is the cap-
ital city of Peru, and Callao is the adjacent main port;
together they have a population of 8,239,891, representing
32% of the national population. Lima and Callao accoun-
ted for 78% of all Peruvian AIDS cases reported from 1983
to September 2000 (13) and for 56% of all TB cases
reported in 1999 (12). The research protocol for using
human participants in this study has been reviewed and
approved by the Human Subject Review Committee of the
University of Washington and the Ethical Committee of
the Scientific Research Office at the Cayetano Heredia
University. Informed consent was obtained from the
participants.
From February 1999 to January 2000, we introduced an
active surveillance system to identify HIV-infected adults
with a new event of TB, defined as a first episode of TB or
a relapse, at the 10 public hospitals that provide care for
most HIV-infected persons living in Lima and Callao. Each
of these 10 hospitals has a unit of the National TB Control
Program where every patient with a suspected or con-
firmed diagnosis of TB is referred for further work-up,
treatment, follow-up, or referral. To identify HIV-infected
patients with a new episode of TB, one trained interviewer
periodically visited each of these units. In addition, we
encouraged all clinicians to send clinical specimens for iso-
lation of M. tuberculosis, and all laboratories to submit
such isolates to TB control program reference laboratories
for susceptibility testing.
MDR-TB was defined as resistance to both isoniazid
and rifampin, with or without resistance to other drugs.
Case-patients were adults with previously diagnosed HIV
infection and with a new episode of TB, whose isolates of
M. tuberculosis were MDR-TB. HIV-seropositive controls
were adults with previously diagnosed HIV infection and a
new event of TB, whose isolates of M. tuberculosis were
susceptible to isoniazid or rifampin. HIV-positive status
was defined by previous, repeatedly positive enzyme-
linked immunosorbent assay (ELISA)  confirmed by
immunofluorescence or Western blot.
From February trough September 1999, a total of 972
adult patients with a new episode of smear-positive TB in
Lima and Callao who received care at Ministry of Health
facilities were included in the National TB Control
Program’s surveillance of resistance to anti-TB drugs. Of
these 972, a total of 116 had been previously tested for
HIV: 7 (6%) were HIV seropositive. From the remaining
965 participants who were HIV seronegative or not tested
for HIV infection, we randomly selected a second control
group of 153 participants.
Enrollment, Interview, and Treatment
Both trained interviewers periodically visited each of
the 10 hospitals to identify, enroll, and interview HIV-
infected patients with a new episode of TB. Because clas-
sification as “case” or “control” for HIV-infected patients
was determined by drug susceptibility-test results, which
became available after 3 or 4 months, each HIV-infected
adult with a new episode of TB was eligible to participate,
and interviewers were blinded to susceptibility test results.
One member of the local TB team introduced the inter-
viewer, who explained the study and invited the patient to
participate. Interviewers contacted adults with TB who
were HIV seronegative or of unknown HIV status belong-
ing to the HIV–seronegative control group at their homes,
where they were invited to participate, enrolled, and inter-
viewed. Patients giving written informed consent under-
went a standardized face-to-face interview concerning
demographic characteristics, past and current medical his-
tory, and potential exposures to M. tuberculosis during the
12 months before onset of TB symptoms. Healthcare
workers at each facility followed national guidelines of the
TB and the AIDS control programs in providing further
treatment and follow up of study participants. Data collect-
ed were handled exclusively by the study team, ensuring
confidentiality.
Laboratory Methods
Primary isolations were attempted by using
Lowenstein-Jensen or Ogawa medium at each hospital lab-
oratory and at local reference laboratories serving the
national surveillance study. Susceptibility testing was car-
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National Institute of Health, the national reference labora-
tory for susceptibility testing, or at one of three local
mycobacterium reference laboratories. These laboratories
used the proportion method to determine the sensitivity
profile of each strain (19), using the following critical con-
centrations (µg/mL): isoniazid, 0.2; rifampin, 40; strepto-
mycin, 4; ethambutol, 2; and pyrazinamide, 100. The
National Reference Laboratory underwent external quality
control by the Pan American Health Organization/WHO
Instituto Panamericano de Protección de Alimentos y
Zoonosis (INPPAZ) and performed quality control for the
three local reference laboratories (20).
Data Analyses
SPSS 10.0 software (SPSS, Inc., Chicago, IL) was used
for data entry and analyses. Percentages of MDR-TB were
compared in HIV-positive and HIV-negative patients with
TB, and risk factors for MDR-TB in HIV-infected patients
were explored by calculation of odds ratios (OR) for
dichotomous variables. Medians of continuous variables
were compared by using Student t test for independent
samples.
Results
Characteristics of Patients with TB
Of 415 HIV-seropositive patients diagnosed and repor-
ted with a new episode of TB (on the basis of acid-fast
smear or culture results or on clinical characteristics) at the
10 hospitals during the study period, 157 (38%) were not
interviewed: 87 had already left the hospital and could not
be located at referral health centers, 67 were in poor clini-
cal condition and unable to answer the questionnaire, and
3 declined to participate. The remaining 258 seropositive
participants interviewed averaged 32 years of age (range
18 to 62) and reported 9.8 years of education; 77% were
men, 57 % single, and 20% had had at least one previous
episode of TB. Isolation of M. tuberculosis was attempted
in 239 (93%); 135 were culture-positive, 61 were smear
positive for acid-fast bacilli, and 62 were diagnosed on the
basis of clinical criteria. Drug-susceptibility testing was
requested for all positive cultures and completed on 81,
who were the focus of subsequent analyses; the remaining
strains were lost before or during transport to the National
Reference Laboratory for susceptibility testing.
Of the 153 TB patients randomly selected as controls
without known HIV infection, we located 110; 108 agreed
to participate. They averaged 29.3 years of age (range 18
to 80) and reported 10.3 years of education; 57% were
men, 52% single, and 9.3% had had at least one previous
episode of TB.
Table 1 presents characteristics of participants with and
without known HIV infection for whom drug-susceptibili-
ty testing was completed. Because HIV infection in Peru
disproportionately affects men who have sex with men,
HIV-seropositive persons were more often men and less
often married, divorced, or widowed; family income and
family ownership of the home were more common among
those not known to have HIV infection. More importantly,
previous history of TB or TB prophylaxis was significant-
ly more common in HIV-infected participants, as was his-
tory of contact with hospitals.
Drug-Susceptibility Test Results
The prevalence of MDR-TB was 43% in the 81 HIV-
seropositive patients with available susceptibility test
results and 3.9% in the 965 patients whose HIV status was
negative or unknown (p < 0.001); only 1 (0.9%) of 108
patients whom we randomly selected and interviewed
from this group of 965 TB patients had an MDR-TB iso-
late (Table 2). The prevalence of resistance to any drug
was also higher in M. tuberculosis isolates from HIV-pos-
itive patients than in isolates from the 965 without known
HIV infection.
Drug-susceptibility test results were available for 26
(16.6%) of the 157 HIV-seropositive patients we did not
interview; 35% of these patients had MDR-TB, not signif-
icantly different from the 43% of those we did interview
(p = 0.44).
HIV Patients with MDR-TB and with Non–MDR-TB
Of HIV-seropositive participants with TB (Table 3),
MDR-TB was significantly associated with TB diagnosed
at hospital A (OR 3.7, 95% confidence interval [CI] 1.3 to
10), with employment during the 12 months before the
onset of symptoms, and with exposure to TB at work, but
not with age, sex, marital status, education level, crowding
in the home, or low income. MDR-TB was not significant-
ly associated with previous episodes of TB or with TB pro-
phylaxis; the proportion who had received TB prophylaxis
or had a previous episode of treatment for TB was 17
(49%) of 35 with MDR-TB versus 20 (43%) of 46 without
MDR-TB (OR 1.2, 95% CI 0.5 to 3.0).
Hospital Characteristics
Table 4 lists the 10 major public hospitals in Lima and
Callao by number of persons with newly diagnosed AIDS
reported during 1999, number with TB diagnosed during
1999, number of HIV-infected patients with a new event of
TB during the study, and percentage of isolates of M.
tuberculosis identified as MDR-TB. All but one of the
MDR-TB cases were identified in the three hospitals
reporting the largest number of HIV-seropositive patients
with a new event of TB during 1999.
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Interviewed patients with (N = 81) or without (N = 177)
susceptibility results were similar with respect to age,
years of education, family income, symptom duration,
time since previous TB, TB prophylaxis in the past, crowd-
ing in the home, gender, marital status, home ownership,
and employment; and during the past 12 months, exposure
to TB at work, exposure at home, ambulatory care at health
centers, ambulatory care at hospitals, inpatient hospital
care, and participation in HIV or TB support groups.
History of previous TB was somewhat more frequent in
those tested (27%) than in those not tested (17%, p = 0.09),
and history of Pneumocystis carinii pneumonia (PCP) pro-
phylaxis was more frequent among those tested (50%) than
in those not tested (32%, p < 0.01).
Discussion
This study documents high rates of MDR-TB in HIV-
infected persons with TB receiving care at public hospitals
in Lima and Callao; MDR-TB was 11 times more common
in these patients than in 965 TB patients without known
HIV infection in Lima and Callao. In comparison to per-
sons having TB without known HIV infection, the HIV-
infected patients with TB had higher frequency of contact
with health centers and hospitals, and MDR-TB was found
mainly in patients receiving care at the three hospitals
serving the largest number of HIV-infected patients with
TB. Although participants with HIV infection more often
had had previous episodes of TB, and presumably, only the
HIV-infected persons had received TB prophylaxis, these
factors were not significantly associated with MDR-TB in
the HIV-infected patients with TB. 
The 43% prevalence of MDR-TB among HIV-infected
persons with TB found in this study is higher than the
36% previously found in Italy (21), and the 28.3% found
in Argentina, both during epidemics of nosocomial MDR-
TB (1).
Because early clinical manifestations of TB often
develop in HIV-infected persons (3,5), they mark sentinel
cases that first indicate outbreaks of nosocomial transmis-
sion of TB and may represent a larger number of nosoco-
mial transmission of TB.
Three factors drive TB transmission: the rate of expo-
sure of susceptible to infectious persons, the efficiency of
transmission per exposure, and the average duration of
infectiousness once infection has occurred (22). For HIV-
infected persons, higher exposure to TB in general could
easily result from routine periodic visits to clinical settings
also frequented by patients with TB (as occurs in Lima and
Callao, where most persons with HIV infection attend
HIV/AIDS clinics located at large hospitals); or from the
mixing of HIV-infected patients with TB patients in these
settings because of the archaic practice of mixing patients
who have communicable diseases (like TB and HIV infec-
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Table 1. Demographic characteristics, past medical history, and potential exposures to tuberculosis (TB) of participants with and 
without known HIV infection
a 
HIV-infected (n = 81) 
Negative or unknown  
HIV status (n = 108)   
Variable  Mean ± SD, or %  Mean ± SD, or %  p value or  OR (95% CI)
b 
Age  31.6 ± 7.0  29.3 ± 11.9  0.13 
Male  80  57  3.0 (1.6 to 5.9) 
Marital status       
Single  59  52  0.42 
Married  9  20  0.05 
Divorced/widowed   11  28  <0.01 
Cohabitant  21  0  <0.01 
Y of education  9.6 ± 2.8  10.3 ± 2.1  0.08 
No. residents/no. bedrooms  3.0 ± 2.0  2.8 ± 1.4  0.48 
Family income  603 ± 333  845 ± 404  <0.01 
Family owns home  75  88  0.4 (0.2 to 0.9) 
Employed
d  63  28  4.4 (2.4 to 8.2) 
Exposure to TB at work
c  17  3  7.3 (2.0 to 26.4) 
Exposure to TB at home
c  16  1  20 (2.6 to 160) 
Previously treated TB
e  27  9  3.6 (1.6 to 8.3) 
Ambulatory care at health centers
d  21  5  5.5 (1.9 to 16) 
Ambulatory care at hospitals
d  40  1  70 (9.3 to 526) 
Inpatient care
d  14  0  <0.001 
Inpatient MoH hospitals
d  11  0  <0.001 
Any exposure to hospital
d  44  1  86 (11.4 to 644) 
TB prophylaxis
e  22  0  <0.001 
aOR, odds ratio; CI, confidence interval; MoH, Ministry of Health. 
bp values proved when comparing means or when one column had a value of 0.
 
cExposure to someone with TB at work or at home during the 12 months before onset of symptoms. 
dVariables reported by patients to have occurred during the 12 months before onset of symptoms. 
eEver in the past. tion) in large multiple-bed wards. MDR-TB case-patients
tend to be selectively hospitalized because they do not
respond to routine therapy.
Conditions that increase exposure to TB, such as over-
crowding, long waiting times in clinics, sharing of facili-
ties, and large open multiple-bed wards, are common in
medical institutions in the developing world. Increased
efficiency of transmission per exposure could occur if
HIV-related immunosuppression increases host suscepti-
bility to acquisition of infection by M. tuberculosis in gen-
eral or by MDR-TB strains of TB in particular. 
Several factors could prolong the duration of infec-
tiousness of MDR-TB in HIV-immunosuppressed persons,
including continued use of isoniazid- and rifampin-based
regimens as initial therapy for TB in HIV-infected persons,
even during ongoing outbreaks of MDR-TB transmission.
Patients receiving ineffective treatment will not improve
and will more often use clinical services as outpatients and
as inpatients, increasing the exposure to MDR-TB of other
patients. In addition, increased frequency of atypical clini-
cal pictures and smear-negative results, relatively common
features in HIV-infected patients with TB, can contribute
to delayed diagnosis and prolonged infectivity.
Evidence suggests that HIV infection favors the emer-
gence of acquired drug resistance in individual patients
during treatment (23,24). HIV-infected persons have a
higher risk for acquisition of isolated rifampin resistance
(25,26), and once- or twice-weekly rifamycin-based regi-
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Table 2. Drug-susceptibility profiles of Mycobacterium tuberculosis isolates from participants with and without known HIV infection  
  HIV negative or unknown status 
HIV positive patients  Interviewed patients  All patients 
Characteristic  N (%)  N (%)  N (%) 
Total no. tested for drug resistance  81 (100)  108 (100)  965 (100) 
Fully susceptible isolates  28 (35)  92 (85)  789 (82) 
Any resistance  52 (65)  16 (15)  76 (18) 
Any H resistance  42 (52)  11 (10)  110 (10) 
Any R resistance  39 (48)  2 (2)  53 (6) 
Any E resistance  19 (24)  0 (0)  27 (3) 
Any S resistance  39 (48)  12 (11)  88 (9) 
Any Z resistance  28 (35)  NA  NA 
Multidrug resistance  35 (43)  1 (1)  38 (3.9) 
Only HR resistance  3 (4)  NA  NA 
HRZ resistance  25 (32)  NA  NA 
HRESZ resistance  11 (14)  NA  NA 
aNA, not available; H, isoniazid; R, rifampin; E, ethambutol; S, streptomycin; Z, pyrazinamide; HRZ resistance includes any strain resistant at least to H and R and Z. 
Table 3. Demographic characteristics, past medical history, and potential exposures to TB of HIV-infected participants with MDR-TB  
and without MDR-TB
a 
 
 
HIV-infected with  
MDR-TB (n = 35); 
HIV-infected without 
MDR-TB (n = 46);     
Variable  Mean ± SD or %  Mean ± SD or %  p value  OR (95% CI) 
Employed
b  46  76    0.3 (0.1 to 0.7) 
Exposure to TB at work
c  6  26    0.2 (0.04 to 0.8) 
Exposure to TB at home
c  20  13    1.7 (0.5 to 5.5) 
Previously treated TB
d  29  26    1.1 (0.4 to 3.0) 
Duration of symptoms  6.7 ± 5.4  7.8 ± 6.6  0.44   
Ambulatory care at health centers
b  14  26    0.5 (0.2 to 1.5) 
Ambulatory care at hospitals
b  43  37    1.3 (0.5 to 3.1) 
Ambulatory care at hospitals
e  3924 ± 5749  2737 ± 3361  0.48   
Inpatient care
b  17  11    1.7 (0.5 to 6.1) 
Inpatient MoH hospitals
b  11  11    1.1 (0.3 to 4.3) 
Days of hospitalization
b  18 ± 11  30 ± 26  0.36   
Diagnosed at hospital “A”  80  52    3.7 (1.3 to 10) 
Any exposure to hospital
b  51  39    1.6 (0.7 to 4.0) 
HIV support group
b  11  7    1.9 (0.4 to 8.9) 
TB prophylaxis
d   26  20    1.4 (0.5 to 4.1) 
Mo. of TB prophylaxis  6.7 ± 5  4.4 ± 3.3  0.27   
PCP prophylaxis
d  57  44    1.7 (0.7 to 4.2) 
Extrapulmonary TB  29  44    0.5 (0.2 to 1.3) 
aMDR-TB, multidrug-resistant tuberculosis; OR, odds ratio; CI, confidence interval; MoH, Ministry of Health; PCP, Pneumocystis carinii pneumonia.
  
bVariables reported by patients to have occurred 12 months before onset of symptoms. 
cExposure to someone with TB at work or at home 12 months before onset of symptoms. 
dEver in the past. 
eAs a continuous variable: total minutes of exposure 12 months before onset of symptoms. mens increase the risk for acquired rifamycin resistance in
TB patients with advanced HIV disease (27–29). MDR-TB
is more often a consequence of addition of rifampin resist-
ance than of addition of isoniazid resistance (22).
Limitations of this study included the fact that TB cases
with HIV infection were recruited from hospitals where
patients with known HIV infection receive care in Lima,
whereas HIV-negative controls were recruited from non-
hospital clinics. However, methodologic features and
results of this evaluation suggest that results may be gen-
eralizable to all HIV-infected patients with TB receiving
care within the Ministry of Health system in Lima and
Callao. Of 457 new episodes of TB in HIV-infected per-
sons >18 years in Lima and Callao during 1999 (12), we
identified 415 cases (91%) through the TB units at each of
these 10 hospitals during the 12-month study. We system-
atically interviewed HIV-infected patients well in advance
of knowing whether they had MDR-TB, and we systemat-
ically interviewed a random sample of TB patients without
known HIV infection from a larger representative sample
of TB patients from Lima and Callao. Participants with
known HIV infection were selected consecutively and
patients without known HIV infection were selected ran-
domly from all case-patients of TB receiving care at pub-
lic health services. Comparisons of those interviewed ver-
sus not interviewed, and those tested and not tested for
drug susceptibility suggested no bias, except that those
tested had somewhat higher frequencies of previous TB
and of PCP prophylaxis. The latter could reflect greater
immunosuppression or greater contact with the medical
care system. Although both could have biased results
toward higher estimates of MDR-TB prevalence among
HIV-seropositive patients, a previous history of TB or of
TB prophylaxis was not associated with MDR-TB.
We were unable to interview all HIV-positive patients
with TB diagnosed during the study, raising the question of
whether the prevalence of MDR-TB was higher in those
we interviewed than in those not interviewed. However,
the 43% frequency of MDR-TB in those we interviewed
did not differ significantly from the 35% prevalence of
MDR-TB in the 26 patients who we did not interview for
whom susceptibility testing was performed. Finally, con-
cerning the fact that we did not obtain HIV serologic find-
ing from all of the 108 controls with negative or unknown
HIV status, if the prevalence of HIV had been higher than
the 2.3% prevalence observed during prospective testing in
Lima in 1999, such misclassification bias would only have
reduced the differences observed between groups.
Community-based studies throughout the United
States have documented increased prevalence of MDR-
TB in HIV-infected people (2), and in a recent report of
several surveys (30), MDR-TB was found more often in
HIV-infected patients than in HIV-uninfected patients, but
after adjustment for previous treatment for TB the differ-
ence between HIV-infected and HIV-uninfected patients
was no longer statistically significance. However, in our
survey, even after eliminating patients with history of
prior episodes of TB or TB prophylaxis, MDR-TB was
still seen in 18 (43%) of 44 isolates from HIV-infected
persons versus 24 (3%) of 814 HIV-negative controls
(p < 0.001).
Conclusion
Although rigorous compliance with infection control
recommendations (31), particularly those related to engi-
neering control, is difficult in developing countries, the
combined epidemics of TB, MDR-TB, and HIV/AIDS
make infection control measures essential. WHO guide-
lines recommend a hierarchy of controls (administrative,
environmental, and personal respiratory protection), many
of which entail little or no cost (32). Minimal measures
must include strict respiratory isolation for patients with
confirmed or suspected TB and mandatory wearing of
appropriate masks for persons entering all patient rooms,
for patients leaving their rooms when unavoidable, and for
patients with cough when seen in clinics. The efficacy of
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Table 4. Ranking of hospitals by number of newly diagnosed cases of AIDS, tuberculosis (TB), HIV, and TB co-infection, February 
1999–January 2000
a,b 
 
Hospital 
No. AIDS patients 
reported during 
1999
c 
No. TB patients 
diagnosed during 
1999 
Total no. HIV-infected 
patients with a new 
diagnosis of TB 
No. (%) HIV-infected 
patients with a new 
diagnosis of TB interviewed 
No. MDR-TB ÷ total drug 
susceptibility test results 
available (%) 
A  154  1,985  204  116 (57)  28/52 (54) 
B  60  723  49  40 (82)  4/9 (44) 
C  139  1,068  41  24 (59)  2/7 (29) 
D  10  891  37  29 (78)  0/4 (0) 
E  33  635  33  21 (64)  0/5 (0) 
F  95  608  29  11 (38)  0/1 (0) 
G  9  425  12  11 (92)  0/1 (0) 
H  30  169  6  4 (67)  0/1 (0) 
I  4  130  3  1 (33)  0/0 (NA) 
J  2  131  1  1 (100)  1/1 (100) 
Total  554  6,765  415  258  35/81 (43) 
aAmong those co-infected with TB and HIV, the number (%) with MDR-TB. 
bMDR-TB; multidrug-resistant tuberculosis.
 
cNumber of AIDS cases reported to the National AIDS and STD Control Program. these essential measures to avert TB transmission in
healthcare settings have been demonstrated (33).
Segregating persons with TB from those with HIV in indi-
vidual rooms with negative air flow, establishing safer spu-
tum sampling collection procedures, improving the labora-
tory support for early identification of TB and of MDR-
TB, and providing more effective treatment regimens to
patients at increased risk for MDR-TB are necessary. HIV
testing of patients with TB and susceptibility testing of M.
tuberculosis isolates from HIV-infected patients should be
routine in settings where outbreaks or endemic transmis-
sion of MDR-TB is occurring in HIV-infected patients.
Nosocomial MDR-TB transmission at hospital A has
been ongoing since 1997. Recently published IS6110
restriction fragment length polymorphism analysis of M.
tuberculosis strains collected between July 1997 and April
1999 and belonging to HIV-positive inpatients clearly
implicate nosocomial transmission of MDR-TB in this
hospital (34). Similarly, outbreaks of nosocomial MDR-
TB in HIV-infected persons have emerged first in New
York, Buenos Aires, and Lima (settings providing hospital-
based care, including antiretroviral therapy, for HIV-
infected persons). Unrecognized MDR-TB outbreaks in
other developing countries are likely. As  delivery of anti-
retroviral therapy for HIV in developing countries pro-
ceeds, nosocomial exposure of HIV-infected persons to TB
must be minimized. More effective surveillance, preven-
tion, and treatment for MDR-TB are essential.
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